{"nctId":"NCT00251758","briefTitle":"Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn","startDateStruct":{"date":"2005-12"},"conditions":["Gastroesophageal Reflux Disease"],"count":908,"armGroups":[{"label":"Dexlansoprazole MR 60 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Dexlansoprazole MR"]},{"label":"Dexlansoprazole MR 90 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Dexlansoprazole MR"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Dexlansoprazole MR","otherNames":["TAK-390MR","Kapidex","Dexilant"]},{"name":"Dexlansoprazole MR","otherNames":["TAK-390MR","Kapidex","Dexilant"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with Non-Erosive Gastroesophageal Reflux Disease identifying their main symptom as heartburn.\n\n  * History of episodes of heartburn for 6 months or longer prior to screening.\n  * History of episodes of heartburn for 4 or more days during the 7 days prior to Day -1 as recorded in the electronic diary.\n\nExclusion Criteria:\n\n* Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists, sucralfate, misoprostol or prokinetics throughout the study\n* Erosive Esophagitis seen on endoscopy during study screening.\n* Co-existing diseases affecting the esophagus.\n* Abnormal laboratory values that suggest significant clinical disease.\n* Known acquired immunodeficiency syndrome (AIDS)\n* Females pregnant or lactating.\n* History of Alcohol abuse.\n* History of Cancer within 3 years prior to screening.\n* Chronic (\\>12 doses per month) use of nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors\n* Use of antacids (except for study supplied GelusilÂ® )\n* Use of drugs with significant anticholinergic effects\n* Need for continuous anticoagulant (blood thinner) therapy\n* Endoscopic Barrett's esophagus and/or definite dysplastic changes in the esophagus\n* History of dilatation of esophageal strictures, other than a Schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter)\n* Current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition\n* History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer\n* Subjects who, in the opinion of the investigator, are unable to comply with the requirements of the study or are unsuitable for any reason.\n* Acute upper gastrointestinal (UGI) hemorrhage within 4 weeks of the Screening endoscopy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median","description":"The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","spread":null},{"groupId":"OG001","value":"45.7","spread":null},{"groupId":"OG002","value":"52.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean","description":"The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.9","spread":"25.7"},{"groupId":"OG001","value":"44.8","spread":"33.8"},{"groupId":"OG002","value":"49.1","spread":"34.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median","description":"The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","spread":null},{"groupId":"OG001","value":"72.3","spread":null},{"groupId":"OG002","value":"76.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean","description":"The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.6","spread":"34.1"},{"groupId":"OG001","value":"62.0","spread":"34.5"},{"groupId":"OG002","value":"64.4","spread":"34.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0},"commonTop":["Gastrointestinal and Abdominal Pains (Excl Oral and Throat)","Upper Respiratory Tract Infections","Headaches NEC","Diarrhoea (Excl Infective)","Nausea and Vomiting Symptoms"]}}}